Position:Emeritus Director
PA:Taryn Hastings
Diabetes Trials Unit
Tel: 01865 857240
Email:rury.holman@dtu.ox.ac.uk
ORCID ID0000-0002-1256-874X
Rury Holman trained in medicine at the University of Bristol in the United Kingdom, founded the University of Oxford Diabetes Trials Unit (DTU) in 1985, and was appointed as the first Professor of Diabetic Medicine at the University of Oxford in 1998. He runs an active Translational Research Group undertaking investigator-led early phase trials of novel therapeutic agents, new medical devices and complex interventions. He also designs and runs investigator-led global cardiovascular outcome trials and is currently joint Chair of EXSCEL and TECOS, and Chief Investigator of ACE and UKPDS. In addition, has a major interest in risk prediction and has co-produced the UKPDS Risk Engine and the UKPDS Outcomes Model, which is used by NICE to assess the potential impact of antidiabetic therapies. Professor Holman has received 16 national and international awards and has published over 370 peer-reviewed papers that have been cited more than 66,000 times.
Manuscript
International Variation in Case Fatality After Major Coronary or Cerebrovascular Events in Individuals With Type 2 Diabetes: Evidence From ADVANCE, TECOS, and EXSCEL
Philip M Clarke et al.
Diabetes Care 2025
Manuscript
Impact of changes in conventional risk factors induced by once-weekly GLP-1 receptor agonist exenatide on cardiovascular outcomes: an EXSCEL post hoc analysis
Ruth L Coleman et al.
Cardiovasc Diabetol. 2025;24:347
Manuscript
Proteomic Pathways across Ejection Fraction Spectrum in Heart Failure: an EXSCEL Substudy
Anthony E. Peters et al.
Sci Rep 2025;15:30170
Manuscript
Evaluating prediction of short-term tolerability of five type 2 diabetes drug classes using routine clinical features: UK population-based study
Pedro Cardoso et al.
Diabetes Obes Metab. 2025;27:4320-4329
Manuscript
Utilization of proteomic surrogates for early detection of unexpected drug benefits
Jessica Chadwick et al.
J Clin Pharmacol. 2025
Manuscript
Risk factors for bone fractures in type 2 diabetes and the impact of once-weekly exenatide: Insights from an EXSCEL post-hoc analysis
Erenesto Maddaloni et al.
Diabetes Res Clin Pract. 2025;223:112125